HUP0302476A3 - Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositins - Google Patents
Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositinsInfo
- Publication number
- HUP0302476A3 HUP0302476A3 HU0302476A HUP0302476A HUP0302476A3 HU P0302476 A3 HUP0302476 A3 HU P0302476A3 HU 0302476 A HU0302476 A HU 0302476A HU P0302476 A HUP0302476 A HU P0302476A HU P0302476 A3 HUP0302476 A3 HU P0302476A3
- Authority
- HU
- Hungary
- Prior art keywords
- gabaainverse
- compositins
- agonists
- pharmaceutical
- preparation
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000000544 cholinesterase inhibitor Substances 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24114500P | 2000-10-17 | 2000-10-17 | |
| PCT/IB2001/001934 WO2002032412A2 (en) | 2000-10-17 | 2001-10-15 | Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0302476A2 HUP0302476A2 (hu) | 2003-11-28 |
| HUP0302476A3 true HUP0302476A3 (en) | 2005-05-30 |
Family
ID=22909428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0302476A HUP0302476A3 (en) | 2000-10-17 | 2001-10-15 | Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositins |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20020151591A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1328294A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2004511512A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20030046509A (cg-RX-API-DMAC7.html) |
| AR (1) | AR030893A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU9411701A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2426120A1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUP0302476A3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL155225A0 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ525103A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20020473A1 (cg-RX-API-DMAC7.html) |
| UY (1) | UY26970A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002032412A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200302918B (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10119862A1 (de) * | 2001-04-24 | 2002-11-07 | Hf Arzneimittelforsch Gmbh | Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen |
| EP1581203A1 (en) * | 2002-12-24 | 2005-10-05 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US8299062B2 (en) * | 2003-09-17 | 2012-10-30 | Franklin Volvovitz | Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction |
| JPWO2005027968A1 (ja) * | 2003-09-19 | 2007-11-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ダウン症候群治療剤 |
| TW200533371A (en) * | 2004-04-15 | 2005-10-16 | Dainippon Pharmaceutical Co | Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative |
| WO2005112946A1 (en) * | 2004-05-14 | 2005-12-01 | The Johns Hopkins University | Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor |
| JP2008509212A (ja) * | 2004-08-09 | 2008-03-27 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害の治療のための新規なキノキサリノンノルエピネフリン再吸収阻害剤 |
| CN100382802C (zh) * | 2005-08-08 | 2008-04-23 | 赵德禄 | 治疗自主神经系统功能紊乱的药物 |
| WO2007139818A2 (en) | 2006-05-22 | 2007-12-06 | The Board Of Trustees Of The Leland Stanford Junior University | Pharmacological treatment of cognitive impairment |
| CA2954376C (en) * | 2006-10-16 | 2019-06-11 | Bionomics Limited | Novel anxiolytic compounds |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| ZA200905537B (en) | 2007-03-01 | 2010-10-27 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| EP2475428B1 (en) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| EA037187B1 (ru) | 2010-02-09 | 2021-02-17 | Дзе Джонс Хопкинс Юниверсити | Способ и композиция для лечения когнитивного расстройства |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| CA2818025A1 (en) | 2010-11-15 | 2012-05-24 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
| CA2828780A1 (en) | 2011-03-02 | 2012-09-07 | Bionomics Limited | Novel small-molecules as therapeutics |
| JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| JP6055817B2 (ja) | 2011-05-12 | 2016-12-27 | バイオノミックス リミテッド | ナフチリジンの調製方法 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| AU2014228512A1 (en) | 2013-03-15 | 2015-10-01 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| EP4032889A1 (en) | 2013-12-20 | 2022-07-27 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| WO2016191288A1 (en) | 2015-05-22 | 2016-12-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| CA2990004C (en) | 2015-06-19 | 2024-04-23 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio, Inc. | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
| AU2019288382B2 (en) | 2018-06-19 | 2024-07-25 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| AU2023324882A1 (en) | 2022-08-19 | 2025-03-20 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4374138A (en) * | 1981-11-13 | 1983-02-15 | Warner-Lambert Company | Antibacterial amide compounds, compositions, and methods of use |
| US5870723A (en) * | 1994-11-28 | 1999-02-09 | Pare, Jr.; David Ferrin | Tokenless biometric transaction authorization method and system |
| US6088683A (en) * | 1996-08-21 | 2000-07-11 | Jalili; Reza | Secure purchase transaction method using telephone number |
| US6016476A (en) * | 1997-08-11 | 2000-01-18 | International Business Machines Corporation | Portable information and transaction processing system and method utilizing biometric authorization and digital certificate security |
| HUP0003258A3 (en) * | 1997-08-25 | 2001-05-28 | Neurogen Corp Branford | Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands |
| US6143760A (en) * | 1997-08-25 | 2000-11-07 | Neurogen Corporation | Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands |
| GB9805561D0 (en) * | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
-
2001
- 2001-10-12 US US09/976,347 patent/US20020151591A1/en not_active Abandoned
- 2001-10-15 NZ NZ52510301A patent/NZ525103A/xx unknown
- 2001-10-15 AU AU9411701A patent/AU9411701A/xx active Pending
- 2001-10-15 WO PCT/IB2001/001934 patent/WO2002032412A2/en not_active Ceased
- 2001-10-15 AR ARP010104836A patent/AR030893A1/es unknown
- 2001-10-15 HU HU0302476A patent/HUP0302476A3/hu unknown
- 2001-10-15 EP EP01974604A patent/EP1328294A2/en not_active Withdrawn
- 2001-10-15 JP JP2002535650A patent/JP2004511512A/ja active Pending
- 2001-10-15 IL IL15522501A patent/IL155225A0/xx unknown
- 2001-10-15 KR KR10-2003-7005292A patent/KR20030046509A/ko not_active Ceased
- 2001-10-15 AU AU2001294117A patent/AU2001294117B2/en not_active Ceased
- 2001-10-15 CA CA002426120A patent/CA2426120A1/en not_active Abandoned
- 2001-10-16 PE PE2001001026A patent/PE20020473A1/es not_active Application Discontinuation
- 2001-10-16 UY UY26970A patent/UY26970A1/es not_active Application Discontinuation
-
2003
- 2003-04-11 ZA ZA200302918A patent/ZA200302918B/en unknown
-
2004
- 2004-08-06 US US10/912,993 patent/US20050009861A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0302476A2 (hu) | 2003-11-28 |
| CA2426120A1 (en) | 2002-04-25 |
| WO2002032412A3 (en) | 2003-03-20 |
| US20020151591A1 (en) | 2002-10-17 |
| KR20030046509A (ko) | 2003-06-12 |
| NZ525103A (en) | 2004-12-24 |
| UY26970A1 (es) | 2002-06-20 |
| AR030893A1 (es) | 2003-09-03 |
| EP1328294A2 (en) | 2003-07-23 |
| AU2001294117B2 (en) | 2006-07-27 |
| IL155225A0 (en) | 2003-11-23 |
| PE20020473A1 (es) | 2002-06-14 |
| WO2002032412A2 (en) | 2002-04-25 |
| ZA200302918B (en) | 2004-04-13 |
| US20050009861A1 (en) | 2005-01-13 |
| AU9411701A (en) | 2002-04-29 |
| JP2004511512A (ja) | 2004-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0302476A3 (en) | Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositins | |
| HUP0400529A3 (en) | Use of chlorpromazine and pentamidine for preparation of pharmaceutical compositions for the treatment of neoplastic disorders | |
| IL147217A0 (en) | New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain | |
| HUP9803018A3 (en) | Use of cyclooxygenase-2 inhibitors for producing pharmaceutical compositions suitable for the treatment and prevention of tumors, tumor-veloted disorders and cachexia | |
| IL196301A0 (en) | Medicament for the treatment of hapatitis c | |
| HU0103558D0 (en) | Pharmaceutical composition for the treatment of stroke and traumatic brain insury | |
| AU5714601A (en) | Methods for prevention and treatment of gastrointestinal disorders | |
| PL366636A1 (en) | Pyranoindazoles and their use for the treatment of glaucoma | |
| IL127943A0 (en) | Pharmaceutical and cosmetic composition for the treatment of skin disorders | |
| HUP0301167A3 (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use | |
| IL155589A0 (en) | Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders | |
| IL150289A0 (en) | Drug combination for the treatment of depression and related disorders comprising mirtazapine | |
| AU2001256855A1 (en) | Preparation for the prevention and treatment of ocular disorders | |
| IL156139A0 (en) | Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain | |
| HUP0300402A3 (en) | Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them | |
| IL158703A0 (en) | 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
| HUP0204391A3 (en) | The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders | |
| EP1455780A4 (en) | NEW BENZODIFURANIMIDAZOLIN AND BENZOFURANIMIDAZOLIN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | |
| IL158632A0 (en) | 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
| HUP0203212A3 (en) | Integrin inhibitors, process for preparation thereof, their use preparation of pharmaceutical compositions and the compositions | |
| GB2370507B (en) | Apparatus for the diagnosis and therapy of neuro-muscular and other tissue disorders | |
| PL366389A1 (en) | 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
| HUP0103017A3 (en) | Pharmaceutical composition for the treatment of diseases caused by impairment of cognitive functions and its use | |
| AU1028501A (en) | Isoquinoline and quinazoline derivatives for the treatment of cns disorders | |
| HUP0302820A3 (en) | Indole derivatives useful for the treatment of cns disorders and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |